The Division of Breast Medicine currently has three physicians providing care within a multidisciplinary Breast Center that also includes surgical and radiation oncologists and radiologists for the integrated care of the Institute’s patients. Therapeutic protocols are drawn not only from the Division’s own investigators, but also from the Clinical Trials Support Unit (CTSU). The Cancer and Leukemia Group B (CALGB), the Princess Margaret Phase II Consortium, select pharmaceutical opportunities, and the Department of Medicine’s Phase I Group. Furthermore, investigations are ongoing of (1) dietary, exercise, and lifestyle change to improve patient outcomes and quality of life, (2) psychological and social ramifications of breast cancer treatment and of interventions to counter adverse influences, (3) infertility resulting from breast cancer treatment, and (4) symptom management. Translational research is conducted under the auspices of the Disease Site working group in Breast Cancer, a collection of the Institute’s scientists and clinical investigators with a focused interest in the prevention, epidemiology, genetics, and biology of breast cancer.